The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension

Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of switching medications in patients with pulmonary arterial hypertension (PAH), a serious condition that affects blood flow in the lungs and can lead to heart problems. Specifically, the trial will look at how changing from one medication called ambrisentan to another called bosentan impacts patients’ health and the way doctors assess their risk levels for complications. Researchers will measure changes in patients' health over a 3-6 month period, focusing on symptoms, physical ability, and potential side effects, especially related to liver health.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of PAH, as determined by a specific heart test. They should have switched from taking ambrisentan to bosentan within the last six months. Participants will be monitored closely during the study, and their health will be assessed to see how the medication switch affects their condition. This trial aims to provide valuable insights that could help doctors make better treatment decisions for patients with PAH.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Confirmed diagnosis of pulmonary arterial hypertension (PAH) by right heart catheterization
• • Documented therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) within the previous 6 months
• Exclusion Criteria:
• • History of severe hepatic impairment
• • Incomplete clinical or laboratory records that prevent risk score calculation
• • Inability to attend clinical follow-up between 3 and 6 months after medication switch